Patients left on chemotherapy for years at NHS trust, report finds
Hospital trust apologises after Royal College of Physicians report finds some patients suffered severe harm at UCHW
Last updated 7 hours ago
Patients with brain tumours were severely harmed and wrongly left on chemotherapy for years while under the care of an NHS trust, a review has found.
Some people were misdiagnosed and given inappropriate courses of treatment, according to a report from the Royal College of Physicians (RCP).
Others were told that if they stopped chemotherapy they would die, despite this not being true.
In one case, a patient was given more than 100 cycles of chemotherapy over 13 years before it was identified that their original diagnosis was incorrect.
They later developed leukaemia as a side-effect of too much chemotherapy.
The report looked at care at University Hospitals Coventry and Warwickshire NHS Trust.
The trust commissioned the review after the retirement of one of its doctors.
He is called Dr Y in the report, but the trust has named him as clinical oncologist Professor Ian Brown.
He worked at the trust from 1996 to 2024.
Colleagues raised concerns about his practice when his patients were handed over to them after he retired in December 2023.
What the review found
Medics found people on long-term repeated cycles of the chemotherapy drug temozolomide (TMZ), which goes against standard practice and national guidelines.
Some patients had also been left on treatment despite their cancer progressing, when moving to best supportive care for their symptoms would have been a better choice.
The RCP said there were multiple examples of extended TMZ treatment being continued despite clear evidence of toxicity or deterioration in the patient's condition, with little or no evidence of benefit.
Overall, the RCP examined 20 cases of care under Prof Brown, though the number of patients affected, including those who have died, is higher.
Of the 20 cases, 15 people were found to have received unsatisfactory care and five were graded as requiring improvement.
The diagnosis was considered insecure in three cases.
Working to strict definitions of harm, the review team concluded six patients had suffered severe harm, five moderate harm and eight low levels of harm.
In the final case, the review team could not reach a judgment on whether the harm was moderate or severe.
The RCP said that, even where harm was graded as lower, reviewers did not underestimate the psychological impact that poor care from a professional in a position of trust can have on patients and their families.
In each of these cases, the report said: "The patient was given unnecessary treatment that was not based on evidence."
In cases of moderate harm, the RCP found evidence of toxicity during treatment.
This included fatigue, shingles causing nerve pain, constipation, rectal bleeding, low sodium levels requiring treatment and low mood.
The long-term risk of developing secondary cancers was also a factor in some gradings of moderate harm.
Cases graded as severe harm featured similar concerns, but the impact was greater or longer lasting, the RCP said.
One patient underwent more than 10 years of chemotherapy after being told they had a glioblastoma, an aggressive form of brain tumour.
This was later found to be a grade 1 pilocytic astrocytoma, a low-grade tumour with potentially normal life expectancy that does not require chemotherapy.
Another patient had treatment for a decade and experienced significant toxicity, including ongoing fatigue, nausea, vomiting and severe shingles requiring hospital admission.
Concerns over oversight and consent
The RCP said Prof Brown did not take up the opportunity to engage with the review.
The investigation also found:
- Patients did not always give proper or full consent to treatment. Reviewers found no record of an accurate and informed discussion with the patient about the non-standard nature of the treatment, or its risks and benefits.
- Prof Brown's contact with patients was often very limited after the initial consultation, and follow-up care was managed by a clinical nurse specialist known as Mr N. The RCP said more direct senior medical oversight was needed and described a very unusual working relationship between the two.
- Effective challenge from the trust's wider neuro-oncology multidisciplinary team was lacking, which the RCP said enabled practice that was not evidence-based to continue over many years.
- Some colleagues professed ignorance of Prof Brown's approach, while others said everyone knew.
- The pharmacy team gave no consideration to the evidence behind the need for prolonged TMZ treatment.
The RCP said: "This was a significant factor in this inappropriate prescribing practice continuing over such a long period of time."
The RCP found pharmacy verification processes were wholly inadequate to address the very unusual treatment decisions made.
Patients were given misleading information, including that they risked dying if they stopped treatment.
When one patient questioned their treatment, they were told by Mr N that Prof Brown was legally bound to prescribe it.
The clinical governance arrangements supporting oversight of the neuro-oncology service were found to be wholly ineffective.
Staff interviewed by the RCP said Prof Brown avoided challenge through a tactic of persistent non-engagement with colleagues.
The RCP said there were multiple opportunities for his non-evidence-based treatment to be challenged, but these were not taken.
There was also evidence that, where concerns were raised and escalated, insufficient action was taken to address them over many years.
The review team said there are potential concerns about the wider culture within the trust and the extent to which it is conducive to delivering safe care.
Recommendations
The RCP said that, in light of its findings in a relatively small sample of cases, the trust should ensure all living patients treated with more than 12 cycles of TMZ have had their case independently reviewed.
It said there is also a large group of deceased patients who received this non-standard chemotherapy regime and may potentially have come to harm.
Work should look at whether these cases also need reviewing, the RCP said.
The trust should also reflect on the opportunities missed to challenge unsafe practice, the report said.
It should also determine whether work is needed across the organisation to ensure patient safety concerns can be safely discussed and promptly addressed.
Reaction from patients and lawyers
Legal firm Brabners, which represents more than 40 patients and is calling for an independent public inquiry, said cases have been referred to the police but no action has been taken so far.
Fiona Tinsley, partner and head of clinical negligence and serious injury at Brabners, said the RCP's findings point to systemic failures in the care and oversight of these patients.
She said: "These treatment failings didn't happen in isolation - they were enabled by repeated failures of oversight across the service for around two decades."
She added: "The RCP's report examined just 20 patients' cases."
"We represent more than 40 people with serious concerns about their care."
"This report cannot be the end point."
Among the patients represented by Brabners is Becky Jones, who was 21 when she was told she had a grade 4 glioblastoma and six to 12 months to live.
She received more than 100 cycles of chemotherapy over more than a decade before it was found she had never had a brain tumour.
Her imaging was found to be consistent with tumefactive demyelination.
Ms Jones said: "For years, I questioned why I was still being given chemotherapy when my scans were stable, but I was repeatedly told that without it I would die."
She said: "I welcome the recommendation that my case, alongside those of every living patient who received more than 12 cycles, should be independently reviewed."
She added: "I now need a full and honest explanation of what happened to me."
Another patient represented by Brabners, David Bown, was diagnosed with a brain tumour in 2016.
He suffered permanent neurological damage following complications after surgery and was later treated with temozolomide for more than eight years.
His condition has deteriorated and he has now lost the ability to speak.
His father, Stephen Bown, said: "What has happened to David has been devastating."
He said: "We cannot change what has happened to David, but we can make sure the truth comes out."
Trust apologises
Professor Andy Hardy, the trust's chief executive, and chairwoman Sue Noyes said in a statement they offered their sincere apologies.
They said: "We are deeply sorry to all the patients and families affected by failures within our neuro-oncology service under the care of retired clinical oncologist Ian Brown."
They also said: "This is far below the standards our patients deserve and that we expect."
They added: "We let you down, and for that we offer our sincere apologies."
The pair said the trust has extended its historical review back to 2005, when national guidance for TMZ was first published, to ensure affected patients are identified and supported.
The trust said it has already taken decisive steps to strengthen its clinical governance and ensure all treatment decisions are made collaboratively.
It said its speaking up processes are also being independently reviewed, so staff feel supported in raising concerns.
The trust said anyone currently receiving cancer treatment there can be reassured it is safe and closely monitored.
It confirmed Mr N has retired from the trust.
The trust has made a formal regulatory referral regarding Mr N to the Nursing and Midwifery Council.
All living patients receiving TMZ at the trust have already had their care reviewed again internally to ensure it aligned with expected standards, the trust said.
A comprehensive independent external clinical review process will also evaluate all living patients who received more than 12 cycles of TMZ under Prof Brown.
The trust said: "We have initiated discussions with the NHS England regional director of patient safety to establish clear requirements and methodology for reviewing the cohort of deceased patients who received non-standard chemotherapy regime."